Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
4875.T
STRONG SELLMediciNova, Inc. · Healthcare · United States · $62M · Avg Vol: $52K/d
COMPANY DESCRIPTION
MediciNova, Inc. is a biopharmaceutical company focused on developing small-molecule therapeutics for serious diseases with unmet medical needs, particularly neurological disorders like ALS and progressive MS. The company's lead clinical candidate, MN-166 (ibudilast), is protected by a robust global patent portfolio and has received multiple orphan drug designations. MediciNova operates a capital-efficient development model, leveraging strategic partnerships and non-dilutive funding to advance its late-stage clinical pipeline.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 1.0M | 0 | 0.4M | -36.0% | 0.6M | 0.4M | 0.4M | -1.2% |
| EPS | -0.29 | -0.17 | -0.23 | -0.24 | — | -0.23 | -0.26 | -0.42 | — |
| Shares | 49.0M | 49.0M | 49.0M | 49.2M | +0.4% | 49.2M | — | — | — |
| Debt | 0.2M | 0.2M | 0.2M | 0.2M | 7.3% | 0.2M | — | — | — |
| Equity | 70.2M | 62.4M | 52.5M | 41.6M | -16.0% | — | — | — | — |
| Op CF | -12.9M | -7.4M | -10.6M | -9.8M | — | -9.5M | — | — | — |
| Inv CF | -40.0M | 39.9M | -697 | -2.9K | — | — | — | — | — |
| Fin CF | 7.9K | 0 | 0 | 0.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 4875.T are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 4875.T | MediciNova, Inc.(you) | $62M | 15 | STRONG SELL |
| CING | Cingulate Inc. | $67M | 13 | STRONG SELL |
| ACRV | Acrivon Therapeutics, Inc. | $72M | 14 | STRONG SELL |
| FLNA | Filana Therapeutics, Inc. | $58M | 9 | STRONG SELL |
| CNTX | Context Therapeutics Inc. | $53M | 10 | STRONG SELL |
| DWTX | Dogwood Therapeutics, Inc. | $55M | 9 | STRONG SELL |
| TIL | Instil Bio, Inc. | $50M | 10 | STRONG SELL |
| ANIX | Anixa Biosciences, Inc. | $95M | 14 | STRONG SELL |
| BDTX | Black Diamond Therapeutics, Inc. | $98M | 15 | STRONG SELL |
| ACET | Adicet Bio, Inc. | $78M | 21 | SELL |
Peer medians: ROE -21.2% · P/E 27.1x · Gross margin 44.5%